Adagene ADAG
NASDAQ ADAG
$3.58 -0.11 (-2.98%)
As of: Sep 4, 2026 · 3:59 PM EDT

Adagene (ADAG) Liabilities and Shareholders Equity (2019 - 2026)

Adagene (ADAG) posted quarterly Liabilities and Shareholders Equity of $78.3 million for Q4 2025, down 12.33% year-over-year from $89.3 million in Q4 2024, and up 17.66% quarter-over-quarter from $66.5 million in Q2 2025.

Analysis

Adagene (ADAG) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends

Adagene (ADAG) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $78.3 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Liabilities and Shareholders Equity fell 12.33% year-over-year to $78.3 million; the TTM figure through Dec 2025 stood at $334.8 million (up 9.5% YoY), while the FY2025 annual figure was $78.3 million, down 12.33% from the prior year.
  • Liabilities and Shareholders Equity climbed to $78.3 million in Q4 2025 per ADAG's latest filing, from $66.5 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $217.9 million in Q2 2021 and bottomed at $135.3 in Q2 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $101.0 million across 5 years, with a median of $95.0 million in 2024.
  • Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity plunged 100.0% — and 2024, when it jumped 74484683.94%.
  • Adagene's Liabilities and Shareholders Equity stood at $189.5 million in 2021, then declined by 19.58% to $152.4 million in 2022, then retreated by 24.06% to $115.7 million in 2023, then retreated by 22.86% to $89.3 million in 2024, then slipped by 12.33% to $78.3 million in 2025.
  • Business Quant data shows ADAG's Liabilities and Shareholders Equity at $78.3 million in Q4 2025, $66.5 million in Q2 2025, and $89.3 million in Q4 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 10.03 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 10.96 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 4.32 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 9.18 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 5.56 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 19.82 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 2.10 Bn
10 Adagene 211.24 Mn 211.24 Mn - 133.58 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 133.58 Mn
Dec 31, 2025 78.26 Mn
Jun 30, 2025 66.52 Mn
Dec 31, 2024 89.27 Mn
Jun 30, 2024 100.78 Mn
Dec 31, 2023 115.73 Mn
Jun 30, 2023 135.30 Mn
Dec 31, 2022 152.40 Mn
Jun 30, 2022 178.56 Mn
Dec 31, 2021 189.51 Mn
Jun 30, 2021 217.86 Mn
Dec 31, 2020 84.26 Mn
Dec 31, 2019 105.89 Mn